Aspiration Therapy Leads to Weight Loss in Obese Subjects: A Pilot Study

Abstract

Background & Aims Obese patients rarely achieve long-term weight loss with only lifestyle interventions. We evaluated the use of endoscopic aspiration therapy for obesity. Aspiration therapy involves endoscopic placement of a gastrostomy tube (A-Tube) and the AspireAssist siphon assembly (Aspire Bariatrics, King of Prussia, PA) to aspirate gastric contents 20 minutes after meal consumption. Methods We performed a pilot study of 18 obese subjects who were randomly assigned (2:1) to groups that underwent aspiration therapy for 1 year plus lifestyle therapy (n = 11; mean body mass index, 42.6 ± 1.4 kg/m2) or lifestyle therapy only (n = 7; mean body mass index, 43.4 ± 2.0 kg/m). Lifestyle intervention comprised a 15-session diet and behavioral education program. Results Ten of the 11 subjects who underwent aspiration therapy and 4 of the 7 subjects who underwent lifestyle therapy completed the first year of the study. After 1 year, subjects in the aspiration therapy group lost 18.6% ± 2.3% of their body weight (49.0% ± 7.7% of excess weight loss [EWL]) and those in the lifestyle therapy group lost 5.9% ± 5.0% (14.9% ± 12.2% of EWL) (P < .04). Seven of the 10 subjects in the aspiration therapy group completed an additional year of therapy and maintained a 20.1% ± 3.5% body weight loss (54.6% ± 12.0% of EWL). There were no adverse effects of aspiration therapy on eating behavior and no evidence of compensation for aspirated calories with increased food intake. No episodes of binge eating in the aspiration therapy group or serious adverse were reported. Conclusions In a pilot study, aspiration therapy appears to be a safe and effective long-term weight loss therapy for obesity. ClinicalTrials.gov, Number: NCT00773903.

Bariatric surgery and surgical devices in obesity management

“…Patients in the intervention arm of the study lost about 50% of the excess weight loss compared with 15% excess weight loss in the control arm. 43 In another study at 6 months 88% of the participants had a mean 41% of excess weight loss. 44 Reported adverse events include abdominal discomfort and bloating, peristomal irritation, bleeding and infection and nausea.…”

Innovative solutions in bariatric surgery

“…The device should be used 20 min after each meal and the ingested food can be aspirated to the toilet. There is a single pilot study (19), reporting EWL of 49% after 1 year and 56% after 2 years. No serious adverse effects have been reported (19).…”

“…There is a single pilot study (19), reporting EWL of 49% after 1 year and 56% after 2 years. No serious adverse effects have been reported (19). The device has FDA registration, despite its controversial way of action.…”

Gastrointestinal devices for the treatment of type 2 diabetes

“…No significant changes in plasma glucose and or other measurements were observed despite the baseline values that were already within the normal range. 18 The device now has a CE mark and is being clinically used in some European countries and has finished enrollment for its US FDA trial. 19 Duodenal Mucosal Resurfacing (DMR) (Revita™ Duodenal Mucosal Resurfacing™, Waltham, MA) is an endolumenal procedure that circumferentially lifts the mucosa layer from the duodenal papilla up to the angle of Treitz by means of a customized balloon and than promotes thermal ablation with another balloon (Fig.…”